Shared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem.
Chadwick
David
D
Gray
Richard
R
D001379:Azathioprine / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D020414:Risk Sharing, Financial
D007166:Immunosuppressive Agents; D001379:Azathioprine